Literature DB >> 26494832

The Dawning of a New Day in CKD Anemia Care?

Colin R Lenihan1, Wolfgang C Winkelmayer2.   

Abstract

Entities:  

Keywords:  VEGF; anemia; hypoxia

Mesh：

Substances：

Year:  2015        PMID： 26494832      PMCID： PMC4814199          DOI： 10.1681/ASN.2015091009

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  17 in total

1.  Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity.

Authors:  Eoin P Cummins; Edurne Berra; Katrina M Comerford; Amandine Ginouves; Kathleen T Fitzgerald; Fergal Seeballuck; Catherine Godson; Jens E Nielsen; Paul Moynagh; Jacques Pouyssegur; Cormac T Taylor
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-17       Impact factor: 11.205

2.  Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.

Authors:  Sonny O Ang; Hua Chen; Kiichi Hirota; Victor R Gordeuk; Jaroslav Jelinek; Yongli Guan; Enli Liu; Adelina I Sergueeva; Galina Y Miasnikova; David Mole; Patrick H Maxwell; David W Stockton; Gregg L Semenza; Josef T Prchal
Journal:  Nat Genet       Date:  2002-11-04       Impact factor: 38.330

Review 3.  Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Trends Pharmacol Sci       Date:  2012-03-06       Impact factor: 14.819

Review 4.  Organ protection by hypoxia and hypoxia-inducible factors.

Authors:  Wanja M Bernhardt; Christina Warnecke; Carsten Willam; Tetsuhiro Tanaka; Michael S Wiesener; Kai-Uwe Eckardt
Journal:  Methods Enzymol       Date:  2007       Impact factor: 1.600

Review 5.  Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes.

Authors:  Brian W Wong; Anna Kuchnio; Ulrike Bruning; Peter Carmeliet
Journal:  Trends Biochem Sci       Date:  2012-11-28       Impact factor: 13.807

Review 6.  Anaemia in kidney disease: harnessing hypoxia responses for therapy.

Authors:  Mark J Koury; Volker H Haase
Journal:  Nat Rev Nephrol       Date:  2015-06-09       Impact factor: 28.314

Review 7.  Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology.

Authors:  Gregg L Semenza
Journal:  Annu Rev Pathol       Date:  2013-08-07       Impact factor: 23.472

8.  Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.

Authors:  Louis Holdstock; Amy M Meadowcroft; Rayma Maier; Brendan M Johnson; Delyth Jones; Anjay Rastogi; Steven Zeig; John J Lepore; Alexander R Cobitz
Journal:  J Am Soc Nephrol       Date:  2015-10-22       Impact factor: 10.121

Review 9.  The VHL/HIF axis in clear cell renal carcinoma.

Authors:  Chuan Shen; William G Kaelin
Journal:  Semin Cancer Biol       Date:  2012-06-13       Impact factor: 15.707

10.  Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients.

Authors:  Anatole Besarab; Elena Chernyavskaya; Igor Motylev; Evgeny Shutov; Lalathaksha M Kumbar; Konstantin Gurevich; Daniel Tak Mao Chan; Robert Leong; Lona Poole; Ming Zhong; Khalil G Saikali; Marietta Franco; Stefan Hemmerich; Kin-Hung Peony Yu; Thomas B Neff
Journal:  J Am Soc Nephrol       Date:  2015-10-22       Impact factor: 10.121
View more
  7 in total

1.  Daprodustat Compared with Epoetin Beta Pegol for Anemia in Japanese Patients Not on Dialysis: A 52-Week Randomized Open-Label Phase 3 Trial.

Authors:  Masaomi Nangaku; Takayuki Hamano; Tadao Akizawa; Yoshiharu Tsubakihara; Reiko Nagai; Nobuhiko Okuda; Kyo Kurata; Takashi Nagakubo; Nigel P Jones; Yukihiro Endo; Alexander R Cobitz
Journal:  Am J Nephrol       Date:  2021-02-09       Impact factor: 3.754

2.  Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease.

Authors:  Edouard R Martin; Mark T Smith; Bradley J Maroni; Qing C Zuraw; Emil M deGoma
Journal:  Am J Nephrol       Date:  2017-03-25       Impact factor: 3.754

3.  Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants with chronic kidney disease.

Authors:  Louis Holdstock; Borut Cizman; Amy M Meadowcroft; Nandita Biswas; Brendan M Johnson; Delyth Jones; Sung Gyun Kim; Steven Zeig; John J Lepore; Alexander R Cobitz
Journal:  Clin Kidney J       Date:  2018-03-09

Review 4.  Efficacy of Different Doses of Daprodustat for Anemic Non-dialysis Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis.

Authors:  Hammad Fadlalmola; Khaled Al-Sayaghi; Abdulqader Al-Hebshi; Maher Aljohani; Mohammed Albalawi; Ohoud Kashari; Alaa Alem; Mariam Alrasheedy; Saud Balelah; Faten Almuteri; Arwa Alyamani; Turki Alwasaidi
Journal:  J Clin Med       Date:  2022-05-11       Impact factor: 4.964

5.  Efficacy and safety of daprodustat in Japanese peritoneal dialysis patients.

Authors:  Hidetoshi Kanai; Masaomi Nangaku; Reiko Nagai; Nobuhiko Okuda; Kyo Kurata; Takashi Nagakubo; Yukihiro Endo; Alexander Cobitz
Journal:  Ther Apher Dial       Date:  2021-05-25       Impact factor: 2.195

Review 6.  Remote ischaemic preconditioning: closer to the mechanism?

Authors:  Jonathan M Gleadle; Annette Mazzone
Journal:  F1000Res       Date:  2016-12-13

Review 7.  Biomarkers of iron metabolism in chronic kidney disease.

Authors:  Glogowski Tomasz; Wojtaszek Ewa; Malyszko Jolanta
Journal:  Int Urol Nephrol       Date:  2020-10-06       Impact factor: 2.370
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.